Cognition Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 2830 www.cogrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics, Inc.

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 - Nov 2nd, 2026 5:30 am
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies - Oct 22nd, 2026 4:00 am
Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development - Oct 13th, 2026 4:59 am
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 - Oct 13th, 2026 4:00 am
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB - Sep 29th, 2026 5:30 am
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference - Sep 8th, 2026 5:30 am
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Aug 6th, 2026 5:10 pm
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Aug 6th, 2026 2:15 pm
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight - Aug 3rd, 2026 8:31 am
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit - Jul 13th, 2026 5:30 am
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% - Jun 24th, 2026 9:47 am
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) - Jun 24th, 2026 6:46 am
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes - Jun 24th, 2026 5:30 am
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 - Jun 16th, 2026 5:30 am
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Jun 2nd, 2026 7:56 am
Cognition Therapeutics Participating in Upcoming Investor Conferences - Jun 1st, 2026 5:30 am
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - May 21st, 2026 5:30 am
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - May 14th, 2026 5:30 am
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs - May 12th, 2026 6:35 am